Methodological shortcomings in assessment of factor VIII concentrate inhibition [5]

Haemophilia

Volumn 13, Issue 5, 2007, Pages 680-681

  Verbruggen, Bert ^a   Van Heerde, W ^a   Budde, U ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Labor Lademannbogen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; EPITOPE; FANHDI; RECOMBINANT BLOOD CLOTTING FACTOR 8; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ALGORITHM; BLOOD SAMPLING; COHORT ANALYSIS; DILUTION; DRUG HALF LIFE; HUMAN; LETTER; METHODOLOGY; PRIORITY JOURNAL; PROTEIN CONTENT; TEMPERATURE SENSITIVITY; THROMBIN TIME;

ALGORITHMS; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; MALE;

EID: 34548358878     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01529.x     Document Type: Letter

References (4)

1. Salvagno GL, Astermark J, Ekman M, et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
2. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001; 86: 1435-9.
3. Vlot AJ, Koppelman SJ, Meijers JC, et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
4. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.